Although not as ubiquitous as antibacterial susceptibility testing, antifungal susceptibility
testing (AFST) is a tool of increasing importance in clinical microbiology laboratories. The …

The clinical application of in vitro antifungal susceptibility testing has been limited by a lack
of reproducibility and uncertain clinical relevance. As a result of several collaborative …

In line with the availability of an increasing array of systemic antifungal agents, there is a
need for accurate, reproducible and predictive susceptibility testing of fungal isolates in …

In comparison with antibacterial agents, drugs for treating systemic fungal infections are
newcomers. Amphotericin B, the first major antifungal agent, was released in the late 1950s …

A multicenter study was conducted to expand the generation and analysis of data that
supports the proposal of a reference method for the antifungal susceptibility testing of …

Candida and Aspergillus species are the most common causes of invasive fungal infections
in immunocompromised patients. The introduction of new antifungal agents and recent …

Development of standardized antifungal susceptibility testing methods has been the focus of
intensive research for the last 15 years. Reference methods for yeasts (NCCLS M27-A) and …

Antifungal susceptibility testing has become an important tool for physicians faced with
making difficult treatment decisions regarding treatment of patients with fungal infections …

The in vitro susceptibility of an infecting organism to the antimicrobial agent selected for
therapy is one of several factors that influence the likelihood that therapy for an infection will …

Prior to the introduction of azoles, no real need for antifungal susceptibility testing (AFST)
existed, as amphotericin B was the only agent available to treat systemic candidiasis …